Tango Therapeutics (NASDAQ:TNGX) Insider Adam Crystal Sells 5,000 Shares of Company Stock

Tango Therapeutics, Inc. (NASDAQ:TNGX) insider Adam Crystal sold 5,000 shares of Tango Therapeutics stock in a transaction that occurred on Wednesday, November 11th. The shares were sold at an average price of $25.00, for a total value of $125,000.00. Following the completion of the sale, the insider directly owned 115,743 shares in the company, valued at $2,893,575. This represents a 4.14% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Adam Crystal also recently made the following trade(s):

• On Monday, November 2nd, Adam Crystal sold 5,000 shares of Tango Therapeutics stock. The stock was sold at an average price of $22.42, for a total value of $112,100.00.
• On Thursday, October 1st, Adam Crystal sold 27,000 shares of Tango Therapeutics stock. The stock was sold at an average price of $24.47, for a total value of $660,690.00.

Tango Therapeutics Trading Up 2.6%

Shares of TNGX traded up $0.65 during mid-day trading on Friday, hitting $25.50. The company’s stock had a trading volume of 2,706,112 shares, compared to its average volume of 4,241,986. The firm has a 50-day simple moving average of $23.53 and a 200 day simple moving average of $22.79. The firm has a market capitalization of $4.32 billion, a P/E ratio of -18.61 and a beta of 1.26. Tango Therapeutics, Inc. has a 1-year low of $7.60 and a 1-year high of $34.39.

Tango Therapeutics (NASDAQ:TNGX) last posted its quarterly earnings results on Monday, November 9th. The company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.04). As a group, sell-side analysts predict that Tango Therapeutics, Inc. will post -1.46 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

TNGX has been the topic of several research analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Tango Therapeutics in a research report on Wednesday, November 4th. Zacks Research downgraded shares of Tango Therapeutics from a “hold” rating to a “strong sell” rating in a report on Tuesday, October 27th. Wall Street Zen downgraded shares of Tango Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, August 15th. Stifel Nicolaus set a $55.00 price objective on shares of Tango Therapeutics in a research note on Friday, October 23rd. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Tango Therapeutics from $46.00 to $47.00 and gave the stock an “overweight” rating in a report on Tuesday, November 10th. Thirteen research analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $45.54.

Recent Tango Therapeutics Headlines

These are some of the TNGX headlines that stood out recently:

• Positive Sentiment: An analyst upgrade was followed by a sharp rise in Tango shares, suggesting the change in rating helped support investor sentiment. Tango Therapeutics stock price up after analyst upgrade
• Neutral Sentiment: Shares moved above their 50-day moving average despite the earnings miss, a technical signal that may indicate improving near-term momentum. TNGX moves above its 50-day moving average
• Negative Sentiment: HC Wainwright lowered its 2026 and 2027 loss-per-share forecasts, including its FY2027 estimate from a loss of $1.54 to $1.75 per share. Wedbush also cut its price target, adding to the cautious analyst signals. Wedbush cuts TNGX price target

Hedge Funds Weigh In On Tango Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of TNGX. Marshall Wace LLP boosted its position in Tango Therapeutics by 16.0% during the third quarter. Marshall Wace LLP now owns 202,937 shares of the company’s stock worth $5,063,000 after purchasing an additional 28,028 shares in the last quarter. Nantahala Capital Management LLC grew its holdings in Tango Therapeutics by 41.2% in the third quarter. Nantahala Capital Management LLC now owns 707,136 shares of the company’s stock valued at $17,643,000 after purchasing an additional 206,477 shares during the last quarter. HighVista Strategies LLC increased its position in shares of Tango Therapeutics by 10.7% in the third quarter. HighVista Strategies LLC now owns 287,769 shares of the company’s stock valued at $7,180,000 after buying an additional 27,699 shares in the last quarter. Bleakley Financial Group LLC increased its position in shares of Tango Therapeutics by 7.0% in the third quarter. Bleakley Financial Group LLC now owns 13,162 shares of the company’s stock valued at $328,000 after buying an additional 860 shares in the last quarter. Finally, First Trust Advisors LP raised its stake in shares of Tango Therapeutics by 20.6% during the 3rd quarter. First Trust Advisors LP now owns 614,160 shares of the company’s stock worth $15,323,000 after buying an additional 104,851 shares during the last quarter. 78.99% of the stock is owned by institutional investors and hedge funds.

Tango Therapeutics Company Profile

Tango Therapeutics is a biotechnology company focused on discovering and developing precision medicines for cancer. Based in Cambridge, Massachusetts, the company aims to develop treatments that exploit genetic differences between cancer cells and healthy cells. Its research centers on synthetic lethality, an approach that seeks to identify vulnerabilities created when cancer cells lose or alter particular genes. Tango uses this strategy to find drug targets and develop investigational therapies for tumors with specific genetic alterations.